China’s mAb and ADC licensing was 3xUS’s in 2024 — will trade tensions slow it?
China’s biopharmaceutical sector saw a rise in oncology drug licensing deals in 2024, particularly for monoclonal antibodies (mAbs) and antibody-drug…
All articles by GlobalData Healthcare
GlobalData Healthcare
-
-
ATS 2025: Sanofi and Regeneron to launch new AIM4 trial for personalised asthma care
At the American Thoracic Society (ATS) 2025 Congress on 19 May, Sanofi and Regeneron announced the launch of a new…
-
ATS 2025: ETI-linked mucus clearance tied to lung function gains in paediatric CF
On 19 May, at the 2025 American Thoracic Society (ATS) International Conference, researchers from Cincinnati Children’s Hospital presented compelling evidence…
-
ATS 2025: Anti–IL-5 therapy cuts exacerbations in coexisting COPD and asthma patients
On 19 May, at the 2025 American Thoracic Society (ATS) International Conference, a poster session by researchers from Ghent University…
-
ATS 2025: Real-world data supports Trikafta as gold standard in long-term CF care
On 18 May at the 2025 American Thoracic Society (ATS) International Conference, a poster presentation by Sivagurunathan Sutharsan and colleagues…
-
ATS 2025: Tezepelumab reduces COPD exacerbations in eosinophilic patients, despite CB
On 18 May 2025, at the American Thoracic Society International Conference, held in San Francisco, California, post hoc findings from…
-
ATS 2025: Nucala reduces COPD exacerbations, regardless of severe event history
On May 18, at the 2025 American Thoracic Society (ATS) International Conference, updated findings from a post hoc analysis poster…
-
Five years, one approval: Europe’s slow march on Alzheimer’s treatments
In April 2025, the European Medicines Agency (EMA) approved Eisai and Biogen’s Leqembi for early-stage Alzheimer’s disease, marking Europe’s first…
-
Revamping US pharma manufacturing: Trump’s executive order faces industry doubts
US President Donald Trump has issued an executive order aimed at easing regulatory challenges for domestic pharmaceutical producers while imposing…
-
Pharma M&A deal value surges by 101% QoQ in Q1 2025 despite US political turbulence
Mergers and acquisitions (M&As) in the biopharmaceutical industry surged 101% in total deal value in the first quarter (Q1) of…